Patents by Inventor Esteban Masuda

Esteban Masuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IGE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME
    Publication number: 20070298440
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: December 8, 2006
    Publication date: December 27, 2007
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Todd Kinsella, Esteban Masuda, Mark Bennett, Justin Warner, David Anderson
  • METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING A C-MYC PROTEIN
    Publication number: 20070244033
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: December 8, 2006
    Publication date: October 18, 2007
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban MASUDA, Todd Kinsella, Justin Warner, Taisei Kinoshita, Mark Bennett, David Anderson
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20070203161
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: February 23, 2007
    Publication date: August 30, 2007
    Inventors: Ankush ARGADE, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20070203162
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: February 23, 2007
    Publication date: August 30, 2007
    Inventors: Hui Li, Ankush Argade, Kin Tso, Sambaiah Thota, David Carroll, Arvinder Sran, Robin Cooper, Rajinder Singh, Somasekhar Bhamidipati, Vanessa Taylor, Esteban Masuda
  • 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
    Publication number: 20070197782
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Application
    Filed: February 16, 2007
    Publication date: August 23, 2007
    Inventors: Jeffrey CLOUGH, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao
  • Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
    Patent number: 7241581
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: July 10, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Kinase Inhibitors And Their Uses
    Publication number: 20070142402
    Abstract: The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity.
    Type: Application
    Filed: December 15, 2006
    Publication date: June 21, 2007
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland
  • Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing a B-Cell Associated Protein
    Publication number: 20070135350
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: February 20, 2007
    Publication date: June 14, 2007
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd Kinsella, Justin Warner, Taisei Kinoshita, Mark Bennett, David Anderson
  • Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein
    Patent number: 7208289
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: April 24, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
    Patent number: 7189523
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: March 13, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing an Adenosine Kinase
    Publication number: 20070054862
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: October 18, 2006
    Publication date: March 8, 2007
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd Kinsella, Justin Warner, Taisei Kinoshita, Mark Bennett, David Anderson
  • Methods and compositions for treating degenerative bone disorders
    Publication number: 20070004626
    Abstract: The present disclosure provides methods and compositions using Syk inhibitory compounds for treating degenerative bone disorders and as prophylactic treatment to prevent bone loss. These treatments may reduce the fracture risk associated with bone loss and compromised bone strength.
    Type: Application
    Filed: June 13, 2006
    Publication date: January 4, 2007
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Polly Pine
  • Methods of treating cell proliferative disorders
    Publication number: 20060276459
    Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
    Type: Application
    Filed: April 18, 2006
    Publication date: December 7, 2006
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Donald Payan, Elliott Grossbard
  • Methods of screening cyclic peptides and identifying targets therefor
    Publication number: 20060275832
    Abstract: The present invention provides compositions and methods for identifying candidate compounds capable of altering a phenotype of a cell that mediate their activity by binding with a specific chaperone of interest. Also provided are methods and compositions for identifying the target of the candidate compound-chaperone complex.
    Type: Application
    Filed: August 30, 2003
    Publication date: December 7, 2006
    Inventor: Esteban Masuda
  • Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase
    Patent number: 7141434
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: November 28, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Publication number: 20060234983
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 19, 2006
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Publication number: 20060211657
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: January 19, 2006
    Publication date: September 21, 2006
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda
  • Methods and compositions for screening for altered cellular phenotypes
    Publication number: 20060147978
    Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.
    Type: Application
    Filed: February 24, 2006
    Publication date: July 6, 2006
    Inventors: James Lorens, Todd Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Liao, Denise Pearsall, Annabelle Friera, Peter Chu
  • Modulators of leukocyte activation, Hck compositions and methods of use
    Patent number: 7067266
    Abstract: The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: June 27, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Annabelle Friera, Brian R. Wong, Esteban Masuda, Mark Powell
  • Methods and compositions for screening for altered cellular phenotypes
    Patent number: 7056687
    Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: June 6, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Todd M. Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Charlene Liao, Denise Pearsall, Annabelle Freiro, Peter Chu